Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | JUN | P05412 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.44 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NNMT | P40261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29552833 | 1.00 | MAPK1 (0.47) | MAPK1JUNNFKB1NFKB2RELA | |
| SCHEMBL1456298 | 0.87 | MAPK1 (0.57) | MAPK1NOTUMKMT2AMEN1KDM4E | |
| SCHEMBL29442775 | 0.87 | MAPK1 (0.57) | MAPK1NOTUMKMT2AMEN1KDM4E | |
| SCHEMBL30670211 | 0.79 | LMNA (0.55) | JUNNFKB1NFKB2RELAKMT2A | |
| SCHEMBL26657700 | 0.79 | ALDH1A1 (0.44) | JUNNFKB1NFKB2RELAKMT2A | |
| SCHEMBL2473041 | 0.79 | CYP1A2 (0.53) | NOTUMKMT2AMEN1KDM4EL3MBTL1 | |
| SCHEMBL20046201 | 0.79 | LMNA (0.55) | JUNNFKB1NFKB2RELAKMT2A | |
| SCHEMBL18979849 | 0.79 | KDM4E (0.56) | MAPK1KDM4EL3MBTL1NNMTALDH1A1 | |
| SCHEMBL31058092 | 0.79 | MAPK1 (0.50) | MAPK1NOTUMKMT2AMEN1KDM4E | |
| SCHEMBL14966683 | 0.79 | MAPK1 (0.50) | MAPK1NOTUMKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 563 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118598859-A | Nitrogenous heterocyclic indole xanthine oxidase inhibitor and preparation method and application thereof | 武汉工程大学 | 2024-09-06 | — | — | CN | claimed |
| CN-118515650-A | STING agonist A02 and synthetic method and application thereof | 河南牧业经济学院 | 2024-08-20 | — | — | CN | claimed |
| CN-118440058-A | N-phenylpyridazine-3-carboxamide compound as well as preparation method and application thereof | 武汉大学深圳研究院 | 2024-08-06 | — | — | CN | claimed |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4727922-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260035384-A1 | COMPOUND CONTAINING CYCLOHEXYL | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | SHANGHAI DEGRON BIOMEDICAL TECH CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-3755331-B1 | AGONISTS OF STIMULATOR OF INTERFERON GENES (STING) FOR USE IN THE TREATMENT OF CANCER | SCRIPPS RESEARCH INST (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20260014147-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2005028452-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
| US-20040152699-A1 | Compounds | ASTRAZENECA AND NPS PHARMACEUTICALS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004026305-A9 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004014881-A2 | '1,2,4'OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | ASTRA ZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
| US-5340808-A | Fused pyridazinoquinazolone derivatives as neurotrophic agents | WARNER LAMBERT COMPANY (US) | 1994-08-23 | — | — | US | disclosed |
| WO-1994011373-A1 | PYRIDAZINOQUINAZOLONE DERIVATIVES AS NEUROTROPHIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152699-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | MAPK1 2417/4885JUN 3270/4885NFKB1 656/4885 |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | MAPK1 3803/4885JUN 4855/4885NFKB1 2224/4885 |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | MAPK1 3571/4885JUN 2510/4885NFKB1 3290/4885 |
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, NR5A1, KLK3 | MAPK1 2144/4885JUN 4119/4885NFKB1 2961/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | MAPK1 2422/4885JUN 2262/4885NFKB1 3370/4885 |
| US-20260035384-A1 | COMPOUND CONTAINING CYCLOHEXYL | CYP11B1, CYP4A11, CYP11B2 | MAPK1 3002/4885JUN 2750/4885NFKB1 1211/4885 |
| US-20260014147-A1 | STAT6 DEGRADERS | STAT6, NCOR1, CBR1 | MAPK1 2558/4885JUN 1586/4885NFKB1 1548/4885 |
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | ELAVL1, ELAVL3, HNRNPL | MAPK1 3753/4885JUN 997/4885NFKB1 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.